Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3962 | Testing procedure for Binding antibodies Wiki | 1.00 |
| drug1960 | Interferon Beta-1B Wiki | 0.58 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
1.5. Why this clinical study? The prevalence of seropositivity following SARS-CoV 2 infection might have its own potential benefits in terms of predicting the end of pandemic and the validity of herd immunity. It is not clear if SARS-CoV 2 infection would have a long-lasting antibody-mediated immunity, and if the antibodies' persistence is dependent on disease severity.depends on the severity of illness. If evidence is provided about the persistence of antibodies that is reflective of the protective immune response, serodiagnosis will be an important tool to identify individuals with various risk for infection, and those who are in need of receiving the forthcoming vaccines. The here proposed prospective clinical study will test the prevalence of seropositivity following SARS-CoV 2 infection in critically ill patients compared to those who do not require intensive care unit (ICU) admission or invasive ventilation with respect to the IgM and IgG levels.
Description: The measurements are dependent on epitope recognitions for synthetic, adsorbed S proteins
Measure: Changes in the levels of S specific antibodies in severely ill patients compared to mild cases. Time: Changes from baseline (4 to 6 weeks) at 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: The measurements are dependent on epitope recognitions for synthetic, adsorbed N proteins
Measure: Changes in the levels of N specific antibodies in severely ill patients compared to mild cases. Time: Changes from baseline (4 to 6 weeks) at 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: Titers of the S specific binding antibodies of SARS-CoV-2 would be assayed as described in the interventions
Measure: S specific binding antibodies of SARS-CoV-2 Time: 4 to 6 weeks and 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: Titers of the N specific binding antibodies of SARS-CoV-2 would be assayed as described in the interventions
Measure: N specific binding antibodies of SARS-CoV-2 Time: 4 to 6 weeks and 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: Titers of the neutralizing antibodies directed against S protein of SARS-CoV-2 would be assayed as described in the interventions
Measure: Neutralizing antibodies directed against S protein of SARS-CoV-2 Time: 4 to 6 weeks and 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: The severity category of critically ill patients would be estimated using an APACHI II score. Minimum score = 0; maximum score = 71.
Measure: The severity category of critically ill Time: Day 0, 4 to 6 weeks and 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: Length of ICU stay from the admission day to the ICU
Measure: Length of ICU Time: For 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: Length of hospital stay from the hospital admission day
Measure: Length of hospital stays Time: For 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: If the patients alive or dead through a telephone interview.
Measure: Alive status at 28-days Time: For 28 days after the onset of symptoms of SARS-Cov2 infectionDescription: If the patients alive or dead through a telephone interview.
Measure: Alive status at 90-day Time: For 90 days after the onset of symptoms of SARS-Cov2 infectionDescription: To correlate the levels of S neutralizing antibodies in severely ill patients compared to mild cases.
Measure: Correlation between the levels of S neutralizing antibodies and disease severity Time: For 16 weeks after the onset of symptoms of SARS-Cov2 infectionDescription: To correlate the levels of N neutralizing antibodies in severely ill patients compared to mild cases.
Measure: Correlation between the levels of N neutralizing antibodies and disease severity Time: For 16 weeks after the onset of symptoms of SARS-Cov2 infectionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports